MEA Genome Editing Market

MEA Genome Editing Market Size (2023 to 2028)

The Genome Editing Market size in the Middle East & Africa was worth USD 0.28 billion in 2023 and is estimated to be growing at a CAGR of 13.98% to reach USD 0.54 billion by 2028 during the forecast period. The Middle East and Africa are willing to fund research and developmental activities in genome editing and molecular biology. Hence this play as a key market driver for MEA genome editing market growth.

The genome editing market in the MEA region is expected to be driven by the proliferation of cancer and other genetic disorders, rising preference for personalized medicine. Also, the increase in the R&D expenditure and development of biotechnology and pharmaceutical industries with the rise in the private and public sector funding further boosts the market growth. In addition, the other factors, such as the increase in the advancements of sequencing and genome editing technologies and the non-labeling of gene-edited products such as Genetically Modified Organisms (GMOs), are fuelling the market growth.

Genome editing has also been estimated that it uses in the treatment of genetic abnormalities, infectious illnesses, and cancer. Furthermore, growing competition between the market players also plays an important role in driving the market growth with the increase in the demand for synthetic genes and the rising market growth of genomic editing. Also, due to the numerous uses of genomic editing in drug development and treatments, the biotech and pharmaceutical industries have now dominated the business. Companies are profiting from creative research concentrating on developing editing tools as the use of CRISPR and ZFN grows.

Along with the drivers, there are rising worries about the dangers and ethical difficulties, which are expected to leave a negative impact on the market. An increase in the costs of genomic equipment is affecting the market growth. Also, ethical concerns related to genetic research, off-target mutation generation, environmental imbalance, editing are some of the key ethical concerns.

This research report on the MEA genome editing market has been segmented and sub-segmented into the following categories:

By Application: 

• Cell Line
• Animal Genetic
• Plant Genetic Engineering

By Technology: 

• CRISPR
• TALEN
• ZFN
• Antisense
• Other Technologies

By End-User: 

• Biotechnological & Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Although the Middle East and Africa have developed R&D, the treatment and associated equipment remain at a high cost. The genome editing market in MEA for few years focused on cures for new emerging and incurable diseases. MEA is also known for its healthcare and health standards, making it a Revenue developer and contributing to market growth.

The Middle East and Africa market is estimated exponential growth in the global genome editing market during the forecast period. The market growth is attributed to the increase in the rising incidences of chronic diseases like cancer, diabetes, and other illnesses with the increasing demand for genetically modified crops due to the increase in the growing population.

The UAE genome editing market is expected to show a promising CAGR during the forecast period. This is because of the increase in demand for technological advancements and developments in the market, with the increase in demand for the synthetic gene.

The Saudi Arabian genome editing market is likely to witness a considerable share in the genome editing market, and it is likely to continue the growth in the forecasted period. In addition, the increase in the initiatives and funding by the government with the rise in the change in the number of genomic projects are also leading to a positive impact on the market growth.

Furthermore, South Africa is also expected to show significant growth in the market in the upcoming years. It is due to growth in the new advancements and technologies in the market with the developments in the R&D activities.

KEY MARKET PLAYERS:

Companies playing a noteworthy role in the MEA Genome Editing Market profiled in the report are Thermo Fisher Scientific, Merck KGAA, Horizon Discovery Group Plc, Genscript Biotech Corporation, Sangamo Biosciences, Integrated DNA Technologies, Lonza Group Ltd, New England Biolabs, Origene Technologies, and Transposagen Biopharmaceuticals.